TIBSOVO (ivosidenib) — DIVESTED
Relapsed/refractory AML with IDH1 mutation
ApprovedDivested to Servier
Key Facts
Indication
Relapsed/refractory AML with IDH1 mutation
Phase
Approved
Status
Divested to Servier
Company
About Agios Pharmaceuticals
Founded in 2008 and headquartered in Cambridge, Massachusetts, Agios Pharmaceuticals has evolved from a pioneering cellular metabolism research company into a commercial-stage rare disease leader. The company's lead product, PYRUKYND® (mitapivat), is FDA-approved for pyruvate kinase (PK) deficiency and is being evaluated in late-stage trials for thalassemia and sickle cell disease. Following the strategic divestiture of its oncology portfolio to Servier for up to $2 billion, Agios is singularly focused on building a leading rare disease franchise rooted in PK activation and cellular metabolism science, targeting hemolytic anemias and other rare conditions.
View full company profileTherapeutic Areas
Other Relapsed/refractory AML with IDH1 mutation Drugs
| Drug | Company | Phase |
|---|---|---|
| REZLIDHIA (olutasidenib) | Rigel Pharmaceuticals | Marketed |